CHMP Favors Expanding Kalydeco Label to Include Young Children With R117H Mutation
May 04, 2020 07:00 am | Marisa Wexler MS
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion for a label extension of the cystic fibrosis (CF) treatment Kalydeco (ivacaftor). If approved by the European Commission, the extension would allow Kalydeco use in patients 6 months and older who weigh at least five kg (about […]
The post CHMP Favors Expanding Kalydeco Label to Include Young Children With R117H Mutation appeared first on Cystic Fibrosis News Today. |
|
|
No hay comentarios:
Publicar un comentario